Workshop on FAIR Data in Plasma Science (FDPS-IV)

The FDPS-IV workshop is intended to provide an overview over successful solutions for collaborative research data management with the goal to make data findable, accessible, interoperable and reusable (FAIR), finally supporting the broader use of data-driven research methods. This includes best practice in day-to-day research work as well as infrastructure tools for handling of research data. Successful examples from plasma research groups and collaborative research centers will be presented and we will discuss the further development of data sharing and reporting standards for the LTP community.

 

12-13 May, 2025

The 4th Workshop on FAIR Data in Plasma Science (FDPS-IV) will be held on 12-13 May, 2025 at the INP in Greifswald, Germany. The event will also offer the option for virtual participation. The workshop is a continuation of annual events on research data management in the low-temperature plasma (LTP) community in the past years. It aims to inform about current developments and to strengthen community exchange on this topic.

 

Venue

The workshop will be held as a hybrid meeting. The on-site event will take place at

Leibniz Institute for Plasma Science and Technology (INP)
Felix-Hausdorff-Str. 2
17489 Greifswald
Germany

 

For more information and Registration application, please, visit:

plasma-mds.org

The FDPS-IV workshop is intended to provide an overview over successful solutions for collaborative research data management with the goal to make data findable, accessible, interoperable and reusable (FAIR), finally supporting the broader use of data-driven research methods. This includes best practice in day-to-day research work as well as infrastructure tools for handling of research data. Successful examples from plasma research groups and collaborative research centers will be presented and we will discuss the further development of data sharing and reporting standards for the LTP community.

 

10TH INTERNATIONAL CONFERENCE ON PLASMA MEDICINE (ICPM10) & 9TH INTERNATIONAL WORKSHOP ON PLASMA FOR CANCER TREATMENT (IWPCT9)

As in previous editions of the conference, the ICPM will bring together professionals from the fields of plasma, medicine, biology and biochemistry in order to develop a common language, to better define key challenges and open questions and to move toward effective solutions. This time it will be organized jointly with IWPCT covering plasma for cancer therapy on Monday, Sep. 9th

Prior to the conference, the traditional Summer School will take place, starting on the weekend, Sunday, Sep. 8th, and going through mornings from Monday, Sep. 9th to Wednesday, Sep. 11th. Registrations for the summer school will be conducted separately from the registrations for the conference.

September 8th – September 13th 2024

Portorož-Portorose, Slovenia

The 10th International Conference on Plasma Medicine (ICPM10), together with 9th International Workshop on Plasma for Cancer Treatment (IWPCT) will be held in Portorož, Slovenia, from Sep. 8th to Sep. 13th 2024. It will be an on-site conference in LifeClass Hotels & Spa Portorož (Hotels Slovenia 5*, Riviera 4*, Grand Hotel Portorož 4*), in the Portorož downtown area on the beach. 

 

HOME

 

 

As in previous editions of the conference, the ICPM will bring together professionals from the fields of plasma, medicine, biology and biochemistry in order to develop a common language, to better define key challenges and open questions and to move toward effective solutions. This time it will be organized jointly with IWPCT covering plasma for cancer therapy on Monday, Sep. 9th

Prior to the conference, the traditional Summer School will take place, starting on the weekend, Sunday, Sep. 8th, and going through mornings from Monday, Sep. 9th to Wednesday, Sep. 11th. Registrations for the summer school will be conducted separately from the registrations for the conference.

Welcome to VPH 2024: Data-Driven Simulation Technologies for Clinical Decision Making Plenary Speakers

Conference at a glance

When

4-6 September 2024

 

Venue

University of Stuttgart
Kollegiengebäude II (K2)
Keplerstr. 17
70174 Stuttgart

Lynne Bilston

Senior Principal Research Scientist, Neuroscience Research Australia and Professor, University of New South Wales (UNSW), Sydney, Australia

 

Natalia A. Trayanova

Murray B. Sachs Professor of Biomedical Engineering and Medicine, Professor of Medicine, Professor of Applied Mathematics and Statistics

Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA

 

Dirk Drasdo

Director of Research INRIA (French National Institut(ion) for Research in Computer Science and Control), Rocquencourt, France

 

Alfons Hoekstra

Professor of Computational Science and Engineering, Informatics Institute, University of Amsterdam

 

Conference at a glance

When

4-6 September 2024

 

Venue

University of Stuttgart
Kollegiengebäude II (K2)
Keplerstr. 17
70174 Stuttgart

Joint meeting ENS-CCA/PRECISION-BTC-NETWORK

It is our great pleasure to welcome you to 4th biennial ENSCCA Meeting, held in conjunction with the Precision-BTC-Network COST Action in the beautiful and historic city of Krakow. Key to the planning and organization of this event has been a focus on fostering collaboration and sharing cutting-edge knowledge. The meeting agenda is full of interesting presentations by prominent speakers with diverse specialties and backgrounds, which cover this meeting’s six session topics: Characterization of BTC, Personalizing Early Diagnosis, Precision Therapeutic Strategies, Patient-centric Approach, Artificial Intelligence to Guide BTC Treatment, and New Preclinical Models. We have also been keen on providing a platform for emerging talent. Young researchers working in the field of biliary cancer will participate in the meeting sessions giving talks and collaborating as moderators; as well as in the meeting’s poster session, where they will have the opportunity to share their original research with their fellow attendees. It is our hope that this poster session—and that the conference generally—will serve as a forum for networking and relationship building. It is through shared effort involving a range of stakeholders from different backgrounds that we best address the challenges related to the prevention, detection and treatment of BTC. As a final point, we would like to extend our sincere gratitude to all those who have contributed to making this meeting a reality. This important event would not have been possible without the generous support of our sponsors and collaborators. Thank you.

With our best wishes for a fruitful and rewarding meeting, The organization team

July 1-2, 2024

Jagiellonian University, Didactic Centre of the Faculty of Law and Administration

Krakow, Poland

 

The annual meeting of the COST action PRECISION-BTC-NETWORK (Management Committee and General Meeting) to be held jointly with the bi-annual ENS-CCA conference. This meeting will focus on biliary tract cancer, covering a wide range of topics including adjuvant treatment, immunotherapy, biomarkers for patients’ selection, the role of artificial intelligence in guiding treatment choice, discussion of the data from the large international European registry on bile duct cancers, development of novel therapeutics with a focus on targeting the microenvironment and the immune system.

 

https://precision-btc.eu/events/actionmeetings

It is our great pleasure to welcome you to 4th biennial ENSCCA Meeting, held in conjunction with the Precision-BTC-Network COST Action in the beautiful and historic city of Krakow. Key to the planning and organization of this event has been a focus on fostering collaboration and sharing cutting-edge knowledge. The meeting agenda is full of interesting presentations by prominent speakers with diverse specialties and backgrounds, which cover this meeting’s six session topics: Characterization of BTC, Personalizing Early Diagnosis, Precision Therapeutic Strategies, Patient-centric Approach, Artificial Intelligence to Guide BTC Treatment, and New Preclinical Models. We have also been keen on providing a platform for emerging talent. Young researchers working in the field of biliary cancer will participate in the meeting sessions giving talks and collaborating as moderators; as well as in the meeting’s poster session, where they will have the opportunity to share their original research with their fellow attendees. It is our hope that this poster session—and that the conference generally—will serve as a forum for networking and relationship building. It is through shared effort involving a range of stakeholders from different backgrounds that we best address the challenges related to the prevention, detection and treatment of BTC. As a final point, we would like to extend our sincere gratitude to all those who have contributed to making this meeting a reality. This important event would not have been possible without the generous support of our sponsors and collaborators. Thank you.

With our best wishes for a fruitful and rewarding meeting, The organization team

WELCOME to ESBiomech 2024: BIOMECHANICS FROM RESEARCH TO PRACTICE

Dear colleagues, it is our great pleasure to invite you to attend the 29th Congress of the European Society of Biomechanics taking place in Edinburgh, Scotland from 30th June to 3rd July 2024. The main theme of the congress – Biomechanics from research to practice – brings the focus on the importance of the dialogue and collaboration between the biomechanics and the clinical communities.

The ESBiomech 2024 scientific programme will include keynote speakers, podium and posters contributions on the latest research developments on all branches of biomechanics.

All traditional ESB sessions and activities will be organized to their full extend – a rich scientific program, interactive and mentoring sessions, students activities, exhibition and networking events.

We are looking forward to welcome you in the beautiful city of Edinburgh!

Dear colleagues, it is our great pleasure to invite you to attend the 29th Congress of the European Society of Biomechanics taking place in Edinburgh, Scotland from 30th June to 3rd July 2024. The main theme of the congress – Biomechanics from research to practice – brings the focus on the importance of the dialogue and collaboration between the biomechanics and the clinical communities.

Future of the European Health Union, MedTech Europe advocates for innovation and competitiveness

Today, the Council of the European Union adopted its conclusions on the Future of the European Health Union, emphasising critical areas such as availability of medical technologies, digitalisation of health, and building more resilient health systems. MedTech Europe calls on Member States to enact policies that support the competitiveness and innovation capacity of the industry to ensure continued and timely access to innovative medical technologies for patients across Europe.

MedTech Europe welcomes the Council’s acknowledgement of the significant challenges related to the implementation of the Medical Devices and In Vitro Diagnostic Medical Devices Regulations (MDR, IVDR). To improve the security of supply for and access to medical devices and in vitro diagnostic medical devices for patients and health systems, it is essential that all the structural deficiencies in the MDR and IVDR are identified and tackled. The conclusions have highlighted several such areas, including governance, innovation, costs, resource and expertise requirements, the particular impact for small- and medium-sized enterprises (SMEs), as well as orphan and paediatric devices.

 

Member States now need to act swiftly to acknowledge the need for comprehensive and cohesive reform of the regulations, with a clear mandate to the European Commission to provide a proposal by end of 2025 upon the conclusion of their Targeted Evaluation.

The Council conclusions also recognise the pivotal role of digital technologies, AI and health data in enhancing patient care, advancing research, and shaping public health policy. Digital policy has been evolving rapidly in the last five years, necessitating a period of adjustment for companies to fully comply with new EU regulations. To ensure smooth implementation, harmonisation in application between Member States and clear guidance on overlapping requirements will be essential. As we move into the next phase when the new requirements start applying to medical technologies, we stress the importance of wide inclusion of all healthcare ecosystem
stakeholders in their implementation.

Building resilient health systems requires a robust, competitive, and innovation-driven industry. While EU regulations promote stability, trust and access to the world’s second-largest medical technology market, they have also raised barriers to entry and present risks of over-regulation. It is critical to adjust the regulatory environment so that it fosters innovation and supports manufacturers of any size, including SMEs, which are crucial for fostering a resilient and dynamic health sector. MedTech Europe hopes to work closely with Member States to find solutions that harmonise the current system and maintain Europe’s competitiveness and attractiveness for innovation to serve patients and health systems in Europe.

Setting the direction for EU health policy over the next five years, Member States now need to be ambitious in implementing their conclusions. Now is the time to make our health systems more patient-centric, digitally advanced, resilient and sustainable.

Today, the Council of the European Union adopted its conclusions on the Future of the European Health Union, emphasising critical areas such as availability of medical technologies, digitalisation of health, and building more resilient health systems. MedTech Europe calls on Member States to enact policies that support the competitiveness and innovation capacity of the industry to ensure continued and timely access to innovative medical technologies for patients across Europe.

MedTech Europe welcomes the Council’s acknowledgement of the significant challenges related to the implementation of the Medical Devices and In Vitro Diagnostic Medical Devices Regulations (MDR, IVDR). To improve the security of supply for and access to medical devices and in vitro diagnostic medical devices for patients and health systems, it is essential that all the structural deficiencies in the MDR and IVDR are identified and tackled. The conclusions have highlighted several such areas, including governance, innovation, costs, resource and expertise requirements, the particular impact for small- and medium-sized enterprises (SMEs), as well as orphan and paediatric devices.

 

Member States now need to act swiftly to acknowledge the need for comprehensive and cohesive reform of the regulations, with a clear mandate to the European Commission to provide a proposal by end of 2025 upon the conclusion of their Targeted Evaluation.

Faster access to clinical trial information in Europe Revised rules for Clinical Trials Information System (CTIS) become applicable

The launch of a new version of the Clinical Trials Information System (CTIS) will allow earlier and more efficient access to information about clinical trials in the European Union (EU) for patients, healthcare professionals and other stakeholders. This is due to the revised transparency rules that become applicable today in Europe.

One of the key changes is earlier availability of information on authorised clinical trials. Importantly, the new rules eliminate the previously available deferral mechanism, which allowed clinical trial sponsors to delay publishing certain data and documents for up to seven years after a trial’s completion to protect commercially confidential information. Under the new rules, approximately 4,000 clinical trials with issued decisions are now publicly accessible through the CTIS search. The CTIS portal will add approximately 500 newly authorised clinical trials per month. This includes ongoing trials that have been transitioned to CTIS from the Clinical Trials Directive. Over the next few months, additional features will be added to the CTIS public portal to further enhance overall usability.

The updated rules strike a balance between transparency of information and protection of commercially confidential information. They benefit patients, because key clinical trial information, that patients flagged as being most relevant for them, is published early. They also benefit clinical trial sponsors because they introduce process simplifications. Finally, they benefit healthcare professionals because the resulting system is more user-friendly, facilitating access to information on clinical trials and enrolment in clinical trials, and also increasing awareness of possible treatment options.

Several resources have been created to help sponsors understand the revised transparency rules, including a user guide and an overview of which data and documents with key information will be published. Dedicated support activities are also being organised, starting with an event on 20 June open to all sponsors of clinical trials including pharmaceutical companies, contract research organisations, small and medium-sized enterprises and academic organisations.

The revised transparency rules were adopted by EMA’s Management Board in October 2023 following a public consultation held between May and June 2023.

The launch of a new version of the Clinical Trials Information System (CTIS) will allow earlier and more efficient access to information about clinical trials in the European Union (EU) for patients, healthcare professionals and other stakeholders. This is due to the revised transparency rules that become applicable today in Europe.

One of the key changes is earlier availability of information on authorised clinical trials. Importantly, the new rules eliminate the previously available deferral mechanism, which allowed clinical trial sponsors to delay publishing certain data and documents for up to seven years after a trial’s completion to protect commercially confidential information. Under the new rules, approximately 4,000 clinical trials with issued decisions are now publicly accessible through the CTIS search. The CTIS portal will add approximately 500 newly authorised clinical trials per month. This includes ongoing trials that have been transitioned to CTIS from the Clinical Trials Directive. Over the next few months, additional features will be added to the CTIS public portal to further enhance overall usability.